SANOFI-ADR (SNY)
US80105N1054 - ADR
Overall SNY gets a fundamental rating of 6 out of 10. We evaluated SNY against 196 industry peers in the Pharmaceuticals industry. SNY scores excellent on profitability, but there are some minor concerns on its financial health. SNY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, SNY could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year SNY was profitable.
SNY had a positive operating cash flow in the past year.
Each year in the past 5 years SNY has been profitable.
SNY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.07%, SNY belongs to the top of the industry, outperforming 87.63% of the companies in the same industry.
Looking at the Return On Equity, with a value of 10.83%, SNY belongs to the top of the industry, outperforming 89.69% of the companies in the same industry.
SNY has a Return On Invested Capital of 12.36%. This is amongst the best in the industry. SNY outperforms 91.24% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SNY is significantly below the industry average of 41.65%.
The last Return On Invested Capital (12.36%) for SNY is above the 3 year average (7.48%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| ROIC | 12.36% |
ROA(3y)5.35%
ROA(5y)5.85%
ROE(3y)9.18%
ROE(5y)10.34%
ROIC(3y)7.48%
ROIC(5y)6.88%
1.3 Margins
Looking at the Profit Margin, with a value of 11.06%, SNY belongs to the top of the industry, outperforming 87.63% of the companies in the same industry.
SNY's Profit Margin has been stable in the last couple of years.
With an excellent Operating Margin value of 21.92%, SNY belongs to the best of the industry, outperforming 88.66% of the companies in the same industry.
In the last couple of years the Operating Margin of SNY has grown nicely.
With a decent Gross Margin value of 69.08%, SNY is doing good in the industry, outperforming 73.20% of the companies in the same industry.
SNY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.92% | ||
| PM (TTM) | 11.06% | ||
| GM | 69.08% |
OM growth 3Y4.23%
OM growth 5Y5%
PM growth 3Y-29.3%
PM growth 5Y-0.74%
GM growth 3Y0.92%
GM growth 5Y0.41%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so SNY is still creating some value.
Compared to 1 year ago, SNY has about the same amount of shares outstanding.
SNY has more shares outstanding than it did 5 years ago.
SNY has a better debt/assets ratio than last year.
2.2 Solvency
SNY has an Altman-Z score of 2.98. This is not the best score and indicates that SNY is in the grey zone with still only limited risk for bankruptcy at the moment.
SNY has a Altman-Z score of 2.98. This is in the better half of the industry: SNY outperforms 72.16% of its industry peers.
The Debt to FCF ratio of SNY is 5.74, which is a neutral value as it means it would take SNY, 5.74 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 5.74, SNY belongs to the best of the industry, outperforming 85.57% of the companies in the same industry.
SNY has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
SNY has a Debt to Equity ratio of 0.20. This is comparable to the rest of the industry: SNY outperforms 43.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 5.74 | ||
| Altman-Z | 2.98 |
ROIC/WACC1.75
WACC7.05%
2.3 Liquidity
SNY has a Current Ratio of 1.00. This is a normal value and indicates that SNY is financially healthy and should not expect problems in meeting its short term obligations.
SNY's Current ratio of 1.00 is on the low side compared to the rest of the industry. SNY is outperformed by 84.02% of its industry peers.
SNY has a Quick Ratio of 1.00. This is a bad value and indicates that SNY is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SNY (0.65) is worse than 88.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 0.65 |
3. Growth
3.1 Past
The earnings per share for SNY have decreased by -8.96% in the last year.
SNY shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.19% yearly.
Looking at the last year, SNY shows a small growth in Revenue. The Revenue has grown by 1.53% in the last year.
SNY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.42% yearly.
EPS 1Y (TTM)-8.96%
EPS 3Y10.81%
EPS 5Y8.19%
EPS Q2Q%-0.57%
Revenue 1Y (TTM)1.53%
Revenue growth 3Y7.52%
Revenue growth 5Y5.42%
Sales Q2Q%7.83%
3.2 Future
SNY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.98% yearly.
SNY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.58% yearly.
EPS Next Y-4.62%
EPS Next 2Y4.3%
EPS Next 3Y5.82%
EPS Next 5Y6.98%
Revenue Next Year6.1%
Revenue Next 2Y6.49%
Revenue Next 3Y6.38%
Revenue Next 5Y5.58%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
SNY is valuated correctly with a Price/Earnings ratio of 12.87.
Compared to the rest of the industry, the Price/Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 90.72% of the companies listed in the same industry.
SNY is valuated cheaply when we compare the Price/Earnings ratio to 31.46, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 11.25, the valuation of SNY can be described as very reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 86.08% of the companies listed in the same industry.
SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.63.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.87 | ||
| Fwd PE | 11.25 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNY is valued cheaper than 94.33% of the companies in the same industry.
SNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNY is cheaper than 82.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.97 | ||
| EV/EBITDA | 7.18 |
4.3 Compensation for Growth
The excellent profitability rating of SNY may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.57
EPS Next 2Y4.3%
EPS Next 3Y5.82%
5. Dividend
5.1 Amount
SNY has a Yearly Dividend Yield of 3.72%.
Compared to an average industry Dividend Yield of 4.06, SNY pays a better dividend. On top of this SNY pays more dividend than 94.85% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.18, SNY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.72% |
5.2 History
The dividend of SNY has a limited annual growth rate of 3.31%.
SNY has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of SNY decreased recently.
Dividend Growth(5Y)3.31%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
SNY pays out 59.74% of its income as dividend. This is a bit on the high side, but may be sustainable.
SNY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP59.74%
EPS Next 2Y4.3%
EPS Next 3Y5.82%
SANOFI-ADR
NASDAQ:SNY (10/21/2024, 5:20:02 PM)
After market: 53.66 0 (0%)53.66
-1.27 (-2.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap134.52B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.72% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.87 | ||
| Fwd PE | 11.25 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)1.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.07% | ||
| ROE | 10.83% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 21.92% | ||
| PM (TTM) | 11.06% | ||
| GM | 69.08% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1 | ||
| Quick Ratio | 0.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-8.96%
EPS 3Y10.81%
EPS 5Y
EPS Q2Q%
EPS Next Y-4.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.53%
Revenue growth 3Y7.52%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y